Study of a new drug to reduce blood vessel swelling in TET2 mutations
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an investigational drug that may reduce swelling (inflammation) inside the blood vessels of people with heart disease and a specific gene change called TET2. This gene change is linked to higher inflammation and heart risks, and the drug aims to lower that risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have heart disease—like a past heart attack, a stent placed more than 6 months ago, or significant plaque in your heart arteries found on a scan.
- You have a TET2 gene change (or no similar gene changes) already found in your blood tests.
- You do not have other active cancers or a history of organ or stem cell transplants.
- You are not taking certain strong anti-inflammatory or immune-suppressing medicines (like steroids, colchicine) by mouth or injection right now or recently.
- You do not have active infections, tuberculosis, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug that lowers inflammation can reduce the risk of another stroke in people with narrowing of a brain artery. The treatment is given after a mild stroke or mini-stroke.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This trial tests a new cell therapy called CT1192 for people with ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. The therapy aims to reset the immune system to stop the disease, and this early study focuses on safety and how the cells work in the body.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This trial tests whether the study drug KP-001 can help reduce symptoms like pain, fatigue, or bleeding caused by certain vascular malformations (abnormal blood vessel growths) that can't be surgically removed or haven't responded to other treatments. It's for people age 2 and older with specific conditions such as common venous malformations, lymphatic malformations, or KTS/CLOVES syndrome.
Hear when a new Vascular Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.